Molecular Neurodegeneration (Nov 2024)

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

  • Marta del Campo,
  • Carlos Quesada,
  • Lisa Vermunt,
  • Carel F. W. Peeters,
  • Yanaika S. Hok-A-Hin,
  • Calvin Trieu,
  • Anouk den Braber,
  • Inge M. W. Verberk,
  • Pieter J. Visser,
  • Betty M. Tijms,
  • Wiesje M. van der Flier,
  • Charlotte E. Teunissen

DOI
https://doi.org/10.1186/s13024-024-00767-z
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 5

Abstract

Read online

Abstract This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.